DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Biomanufacturing Capacity Strategies: Developing a Flexible, Scalable and lean Biomanufacturing system - Overview" report to their offering.
This newly published Report, Biomanufacturing Capacity Strategies: Developing a Flexible, Scalable, and Lean Biomanufacturing System Report, focus on the need for a more reactive and dynamic biomanufacturing approach than is the current industry standard.
Biomanufacturing is common practice in the life sciences industry and has been continually developed and improved for the last two decades. However, as blockbuster drugs reach the end of their patents, treatment is evolving to become more patient-centric and personalized. The mapping of the human genome has allowed for sophisticated and effective new genetic markers and diagnostic methods to be developed, meaning that personalized medicine is becoming a reality. This has a direct impact on manufacturing, with long-term expected production paradigm shifts in the shape of near-patient manufacturing. Moreover, the rise in incidence of viral pandemics has driven a need for quick set-up, disposable, transportable biomanufacturing. This was a contributing factor to Tamiflu being first to market and will very likely be key in the race to stop the Ebola pandemic.
In addition to covering background information on biomanufacturing and capacity approaches, this report will highlight several technologies, methodologies, and business strategies that can be implemented to improve the capacity and flexibility of biomanufacturing.
- Cell Therapy Catapult
- Cobra Biologics
- Pall Corporation
- Smart Consulting Group
Biomanufacturing Capacity Strategies, Opportunities, and Challenges
Biomanufacturing Capacity Innovation as a Solution to Biotechnology Industry Challenges
For more information visit http://www.researchandmarkets.com/research/glpp4v/biomanufacturing